What SHL Medical does

SHL Medical is a Swiss-headquartered, privately held designer, developer, and manufacturer of advanced self-injection drug delivery devices, founded in 1989 by Roger Samuelsson and headquartered in Zug, Switzerland. The company produces autoinjectors (Molly modular platform in 1.0 mL and 2.25 mL formats, Maggie 3.0 mL and 5.0 mL large-volume cartridge-based devices, Reunite dual-chamber autoinjector for lyophilized formulations, and DAI), pen injectors (Quanta for once-weekly cardiometabolic therapies, PPI with Rotaject high-viscosity technology, Madie for growth hormone), the electromechanical Elexy platform with cellular and RFID connectivity, and the Molly Connected Cap add-on. Underlying technology includes the proprietary Needle Isolation Technology (NIT) for pre-attached needle cartridge-based injection, the Rotaject mechanism for highly viscous formulations, and a vertically integrated manufacturing stack spanning in-house mold making through the SHL Advantec subsidiary, 320+ fully electric injection molding machines, automated assembly, testing, and final assembly/packaging services. The company holds 227 active patent families for single-use autoinjectors, described as 2.5x more than its closest competitor.

SHL Medical operates a B2B enterprise business model, selling devices as combination products to pharmaceutical and biotechnology customers rather than directly to patients. Revenue is generated through hardware sales of drug delivery devices plus professional services covering feasibility studies, design, human factors engineering, development, scale-up, regulatory affairs support, quality systems, and final assembly/labeling/packaging. Pricing is quote-based and not publicly disclosed. The customer base spans 30+ pharmaceutical companies on the Molly platform alone, with named customers including AstraZeneca, Sandoz, and Bayer, and product use cases covering all 12 IQVIA-recognized therapy areas across 75+ markets. Go-to-market is enterprise field sales with regional business development heads covering EMEA (Michael McGowan), Americas (Paul Martinez), and APAC (Markus Bauss), supplemented by major industry event participation (CPHI, PODD, Pharmapack) and technical content marketing.

The company operates at industrial scale with 6,000+ employees of 60+ nationalities across manufacturing and engineering locations in Switzerland, Taiwan, Sweden, and the United States (North Charleston, SC and Deerfield Beach, FL), with annual manufacturing capacity reaching up to 700 million devices and cumulative shipments of 1.5 billion autoinjectors. Strategic equity backing from EQT and ATHOS (rounds in 2020 and December 2022) has supported inorganic growth, including the 2020 acquisition of Weibel CDS AG, 2023 acquisition of LCA Automation, and 2024 acquisition of Superior Tooling Inc. A March 2026 strategic collaboration with Thermo Fisher Scientific establishes integrated drug-device manufacturing at Thermo Fisher's Ridgefield, NJ facility, representing a significant expansion of the company's US-based combination product offering.

Name

SHL Medical

Legal name

SHL Medical

Website

https://shl-medical.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

SHL Medical is a Swiss-headquartered, privately held medical device manufacturer founded in 1989 that designs, develops, and produces self-injection drug delivery devices — including autoinjectors, pen injectors, and large-volume cartridge-based systems — for pharmaceutical and biotechnology companies across multiple therapy areas.

Ownership category

akta.pro rank

Product category

Drug Delivery Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Auto-Injectors (Disposable & Reusable) (HLAHAIAB)

akta.pro secondary industries

Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC), Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Drug delivery devices
• Autoinjector manufacturing
• Pen injector systems
• Combination product development
• Self-injection devices

Headquarters

HQ city

Zug

HQ country

Switzerland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Drug Delivery Device Sales: Design, development, and manufacturing of self-injection devices such as autoinjectors and pen injectors for pharmaceutical and biotech companies. Devices are sold as combination products with drugs.
2. Device Development Services: Full end-to-end services from feasibility and device selection through design, development, scale-up, and production. Includes support services like regulatory affairs, quality systems, and supply chain management.
3. Final Assembly, Labeling, and Packaging Services: Complete assembly, labeling, and packaging services for drug delivery devices at facilities in Florida, USA and through alliance partners in Europe.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

SHL Medical designs, develops, and manufactures advanced self-injection drug delivery devices—including autoinjectors, pen injectors, inhaler systems, and micro-dosing devices—for pharmaceutical and biotechnology companies. Its portfolio centers on the Molly modular autoinjector platform (1.0 mL and 2.25 mL), Maggie large-volume cartridge-based autoinjectors (3.0 mL and 5.0 mL), the Reunite dual-chamber autoinjector for lyophilized formulations, the Quanta multi-dose pen injector, the Elexy electromechanical autoinjector, and the Picleo micro-dosing device. The company also provides end-to-end device development services spanning feasibility, design, scale-up, manufacturing, final assembly, regulatory affairs, and quality systems.

Product overview

SHL Medical is a platform-plus-modules company offering advanced self-injection drug delivery solutions. The core product portfolio centers on the Molly modular autoinjector platform (Molly 1.0, Molly 2.25), Maggie large-volume cartridge-based autoinjectors (Maggie 3.0, Maggie 5.0), and Reunite dual-chamber autoinjector for lyophilized formulations, complemented by the Quanta pen injector for weekly cardiometabolic therapies. The company provides comprehensive device development services spanning feasibility, design, development, scale-up, production, and final assembly, with supporting services in regulatory affairs, quality systems, and IP support. Strategic partnerships with Thermo Fisher Scientific enable integrated drug-device solutions, while the Elexy electromechanical autoinjector represents innovation in connectivity and reusability. The company operates vertically integrated manufacturing with capacity up to 700 million devices annually.

Differentiator

Problem solved

Functional benefit

Brands

• Elexy: Electromechanical autoinjector featuring versatility, reusability, connectivity, and ease of use
• Molly
• Maggie
• Reunite
• Quanta
• SHL Advantec
• DAI
• PPI
• Madie
• MDD

Products and services

• Molly 1.0 A 2-step disposable autoinjector built on modular platform technology with 1.0 mL volume capacity, designed for high viscosity drugs and intended to help pharma and biotech customers reduce initial investments and expedite development timelines.
• Molly 2.25 Large-volume variant of the Molly modular autoinjector that delivers higher-volume biologics using a 2-step operation with optional 8mm or 1/2 inch pre-filled syringe needle, supporting formulations up to 50 cP viscosity.
• Maggie 3.0 Cartridge-based large-volume autoinjector built with Needle Isolation Technology (NIT) that accommodates 3.0 mL volumes and supports larger-volume formulations and suspension drugs that pre-filled syringe-based autoinjectors cannot deliver.
• Maggie 5.0 Cartridge-based large-volume autoinjector built with market-proven Needle Isolation Technology (NIT) that supports 5.0 mL fill volumes in both polymer and glass cartridge configurations for high-volume biologic therapies.
• Reunite Innovative three-step dual-chamber cartridge autoinjector built with Needle Isolation Technology (NIT) that supports automated reconstitution and delivery of lyophilized formulations through three-step operation.
• Quanta Automatic multi-fixed-dose pen injector designed for once-weekly cardiometabolic therapies, featuring a no-priming spring-driven mechanism that supports 4-6 doses per device using 1.5 mL and 3.0 mL ready-to-use cartridges.
• Elexy Versatile electromechanical autoinjector combining versatility, reusability, connectivity, and ease of use, with a single interface for both pre-filled syringes (1.0 mL and 2.25 mL) and cartridges (3.0 mL and 5.0 mL), integrated cellular connectivity, and RFID-enabled drug cassettes.
• Picleo (Micro Dosing Device) Micro-dosing device technology that enables precise administration of microliter volumes for intravitreal therapies and other specialty applications requiring microliter-scale dosing.
• Device Development Services End-to-end device development services covering feasibility and device selection, design, development, scale-up, and production for pharmaceutical and biotech customers seeking combination product support.
• Injection Molding In-house injection molding services backed by more than 320 fully electric molding machines (40-420 tons clamping force) with multi-component molding, robotic technologies, and automated material handling.
• Assembly Services Flexible device assembly services using manual, semi-automatic, and fully-automatic assembly machines that scale from low-volume pre-clinical production to high-volume commercial output up to 700 million devices annually.
• Final Assembly, Labeling, and Packaging Complete assembly, labeling, and packaging services for drug delivery devices at SHL's Florida facility and through alliance partners in Europe, including equipment qualification, process development, design transfer, and turnkey assembly.

Quantifiable outcome

• 1.5 billion autoinjectors shipped worldwide
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Thermo Fisher ScientificflagshipStrategic or Co-development Partner · 25 March 2026Strategic collaboration to deliver fully integrated drug-device solutions combining SHL Medical's Molly autoinjector platform with Thermo Fisher's sterile fill-finish and manufacturing capabilities. Partnership expands sterile fill-finish and autoinjector final assembly capacity at Thermo Fisher's Ridgefield, NJ facility, creating end-to-end solutions from drug product to finished device.
• SCHOTT PharmacoreTechnology or Integration · 1 January 2026Joint compatibility studies confirming SCHOTT Pharma's TOPPAC polymer cartridge platform compatibility with SHL Medical's Maggie large-volume autoinjectors (3ml and 5ml configurations), enabling pre-validated solutions for large-volume medication self-administration.
• KymanoxminorImplementation/ SI/ Consulting Partner · 1 September 2024Non-exclusive strategic partnership providing specialized services for combination product development.
• Aptar Digital HealthcoreStrategic or Co-development Partner · 1 June 2024Strategic partnership to integrate connected drug delivery solutions combining SHL Medical's self-injection technologies with Aptar's digital health expertise for improved self-injection therapy monitoring and patient outcomes.
• Superior Tooling Inc.coreStrategic or Co-development Partner · 1 January 2024Acquisition of US-based manufacturer specializing in plastic injection molds to strengthen SHL Medical's manufacturing capabilities and support its new facility in North Charleston, SC. Part of broader strategy for global expansion and in-house manufacturing.
• LCA AutomationcoreStrategic or Co-development Partner · 1 July 2023Acquisition of 100% of shares in Swiss company LCA Automation to enhance SHL Medical's in-house automation and high-precision manufacturing capabilities.
• SHL AdvanteccoreOthersSubsidiary company responsible for mold manufacturing, automation systems, and tooling solutions. Enables vertical integration and in-house manufacturing capabilities.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Emerging players

• Haselmeier: Haselmeier is a German-based drug delivery device specialist focused on pen injectors and autoinjectors with strong presence in diabetes and growth hormone therapy. It is a smaller but direct competitor offering similar modular and custom device development services to pharma customers.
• Aptar Pharma: Aptar Pharma is a primary partner of SHL for connected drug delivery via Aptar Digital Health. Aptar also competes with its own pre-filled syringe closures and drug delivery platforms, making it both an ally and a partial competitor at the device-plus-digital layer.

Direct peers

• Owen Mumford: Owen Mumford is a UK-headquartered specialist in autoinjectors, pen injectors, and safety syringes used for self-administration of biologics and diabetes therapies. It overlaps directly with SHL's Molly autoinjector and pen injector product lines serving the same enterprise pharma combination product market.
• Stevanato Group: Stevanato Group supplies prefilled syringes and integrated drug delivery platforms (including its own device programs) and is a named integration partner of SHL. Both compete for prefilled-syringe-based combination products in the biologics and high-viscosity space.
• Ypsomed: Ypsomed Holding AG is a Switzerland-based rival offering YpsoMate autoinjectors and pen injectors for self-injection of biologics, directly competing with SHL's Molly, Maggie, and Quanta platforms. Both companies are vertically integrated Swiss-headquartered drug delivery specialists serving the same pharma customer base for diabetes, autoimmune, and obesity therapies.
• West Pharmaceutical Services: West Pharmaceutical Services is the largest direct competitor in elastomeric primary packaging and high-value drug delivery devices (e.g., SmartDose, SelfDose, PLG platform). Both companies compete head-to-head for pharma combination product programs in biologics and GLP-1 obesity therapies with similar modular device philosophies.
• Nemera: Nemera is a French drug delivery device manufacturer offering autoinjectors (e.g., Safe'n'Sound), pen injectors, and inhalers. It targets the same pharmaceutical customers and therapy areas as SHL, providing modular custom device platforms for biologics and large-volume subcutaneous delivery.

Broad incumbents

• Becton Dickinson (BD) - Pharmaceutical Systems: BD's Pharmaceutical Systems segment is a major supplier of prefilled syringes (BD Neopak) and safety-engineered drug delivery devices used in combination products with the same pharma customers SHL serves. BD is also a documented integration partner of SHL for high-viscosity biologics delivery.
• Gerresheimer AG: Gerresheimer is a leading global manufacturer of glass primary packaging (syringes, cartridges) and increasingly drug delivery devices (including the Sensile Medical platform). It competes at the drug-device interface with SHL, particularly in glass-based cartridge autoinjectors.

Others

• SCHOTT Pharma: SCHOTT Pharma is a strategic integration partner whose TOPPAC polymer cartridge platform is pre-validated for SHL's Maggie large-volume autoinjectors. While primarily a primary packaging supplier, SCHOTT increasingly competes in the device ecosystem that SHL serves, especially for high-value biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/shl_medical
• YouTubeyoutube.com/shlmedical
• Facebookfacebook.com/SHLMedical
• LinkedInlinkedin.com/company/shlmedical

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SHL Medical